Wegovy HD vs Zepbound: Head-to-Head Weight Loss Comparison
Price verification — October 26, 2026
Some examples and provider price illustrations in this article are estimates, not guaranteed checkout quotes.
- Zepbound (tirzepatide): LillyDirect self-pay: 2.5 mg starts at $299/28 days, 5 mg at $399, and 7.5 mg and above at $449 only with qualifying 45-day refill timing. Higher-dose prices can be higher when those conditions are not met. Supplies may cost extra. Official source
- Wegovy (semaglutide): Wegovy tablet: $149/30 tablets at 1.5 mg, $199 at 4 mg (a temporary $149 4 mg offer may apply), and $299 at 9 mg or 25 mg. Wegovy injection: eligible new patients may pay $199 per 28-day fill for the first two fills at 0.25 or 0.5 mg through Dec. 31, 2026, then generally $349 for standard pen doses. Eligibility and dosage restrictions apply. Official source
These are manufacturer self-pay or listed care-fee examples, not one all-inclusive price or guaranteed prescription. Insurers, clinical visits, pharmacy choice, dosage, supplies, refill conditions and geography can change the amount due.
For the first time, semaglutide matches tirzepatide in weight loss efficacy. Here's how Wegovy HD stacks up against Zepbound on every metric that matters.
Wegovy HD: Semaglutide 7.2mg — 20.7% weight loss (STEP UP)
Zepbound: Tirzepatide 15mg — 20.9% weight loss (SURMOUNT-1)
The gap: Virtually eliminated at these doses
The Numbers Side by Side
| Metric | Wegovy HD (7.2mg) | Zepbound (15mg) |
|---|---|---|
| Mean weight loss | 20.7% | 20.9% |
| ≥20% weight loss | ~50% | ~57% |
| ≥25% weight loss | ~33% | ~36% |
| Mechanism | GLP-1 single agonist | GLP-1/GIP dual agonist |
| Dosing | Once weekly | Once weekly |
| Cardiovascular data | Yes (SELECT trial) | Pending (SURPASS-CVOT) |
| Available as pill | Yes (oral Wegovy 25mg) | No (orforglipron pending) |
| Self-pay cost | TBD (HD), $349+ (standard) | $550+ |
Where Wegovy HD Wins
- Cardiovascular proof: SELECT trial demonstrated 20% reduction in major cardiac events. Zepbound's CV outcomes trial is still running.
- Oral option exists: If you can't tolerate injection-level doses, oral Wegovy 25mg delivers 16.6% weight loss at $149/month. No oral tirzepatide equivalent yet.
- Broader safety database: Semaglutide has been on-market since 2017 (Ozempic), giving it the longest real-world safety record.
Where Zepbound Wins
- Slightly higher efficacy ceiling: At the top dose, tirzepatide edges out semaglutide by a small margin.
- Dual mechanism: GLP-1 + GIP agonism may provide additional metabolic benefits.
- Sleep apnea indication: Zepbound is FDA-approved for moderate-to-severe OSA.
Embody · $149 first mo
Compounded medications are not FDA-approved. Paid link
Compounded Alternatives at Lower Cost
$130/mo sema
Check Eligibility → Paid linkCompounded medications are not FDA-approved.
from $147/mo
Paid linkCompounded medications are not FDA-approved.
The Bottom Line
The efficacy gap between semaglutide and tirzepatide has essentially closed at their highest approved doses. The decision now comes down to cardiovascular data (advantage: Wegovy), cost (advantage: semaglutide ecosystem), additional indications (advantage: Zepbound for sleep apnea), and oral availability (advantage: Wegovy pill). Both are excellent medications.
Sources
- STEP UP trial, semaglutide 7.2mg, 2026
- SURMOUNT-1 trial, tirzepatide 15mg, 2022
- SURMOUNT-5 head-to-head trial, 2024
- SELECT cardiovascular outcomes trial, NEJM 2023